|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: South Africa
Espicom Business Intelligence Ltd, Oct 2011, Pages: 56
THE PHARMACEUTICAL MARKET: SOUTH AFRICA - REVIEW
South Africa has one of the highest rates of HIV and AIDS infections in the world, equivalent to just over 10% of the entire population. As a result, the market for antiretroviral (ARV) drugs looks set to grow, particularly as the government looks at ways to increase the supply of these drugs via the public system. The government has also proposed a National Health Insurance (NHI) scheme, which aims to provide healthcare for all South Africans. This is expected to become law in 2011, with the necessary institutional and organisational structures to start implementing the NHI being in place by March 2012. The NHI will require compulsory contributions from all citizens, with the exception of the poor and unemployed.
South African pharmaceutical prices are reviewed on a regular basis and most recently the Department of Health increased them by 13.2%, a move that was welcomed by the Pharmaceutical Industry Association of South Africa (PIASA), which said the increase helped combat increasing margin pressures experienced three years ago due to mainly imported raw materials against a weakening local currency. The government, although wanting to back the local industry with protectionist measures, could be tempted to procure more drugs from countries like India and China, which can provide a higher volume of drugs for the same tender price compared to local companies.
The South African pharmaceutical market is set to grow at a constant rate over the coming years. According to industry estimates, generics have overtaken branded pharmaceuticals in terms of market volume and this trend is expected to continue, taking into account that the demand for cheaper essential drugs, including antiretroviral drugs, is set to grow. Local manufacturers, notably Aspen Pharmacare and Adcock Ingram, almost exclusively produce generics. In May 2011, Adcock Ingram announced its acquisition of a biosimilar insulin distributor, which would give it the opportunity to become a significant player in the South African diabetes market. In January 2011, Aspen completed the acquisition of the pharmaceutical division of an Australian company.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Canada
The Pharmaceutical Market: South Korea
The Pharmaceutical Market: Latvia
The Pharmaceutical Market: Croatia
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Germany
|
|
|
|
